Randomized controlled clinical study on effect of Chinese compound changjitai in treating diarrheic irritable bowel syndrome.
- Author:
Yun SHEN
1
;
Gan CAI
;
Xu SUN
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Diarrhea; drug therapy; etiology; Drug Therapy, Combination; Drugs, Chinese Herbal; therapeutic use; Female; Humans; Irritable Bowel Syndrome; complications; drug therapy; Male; Middle Aged; Morpholines; therapeutic use; Phytotherapy
- From: Chinese Journal of Integrated Traditional and Western Medicine 2003;23(11):823-825
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo verify the clinical efficacy and safety of the proven Chinese Compound Changjitai (CJT), in treating the diarrheic irritable bowel syndrome (DIBS).
METHODSRandomized controlled open clinical trial design was adopted, 45 patients were randomly divided into two groups, CJT and pinaverium bromide (PVB) were given as treated and control agent respectively. IBS scoring system (BSS), defecation state questionnaire (DSQ) were used to record the changes of the patients' main symptoms before and after treatment.
RESULTSThe total effective rate of CJT group was 83.3%, while that of PVB was 73.3%. CJT was superior in efficacy to that of PVB in improving stool quality, reducing defecation episodes of diarrheic patients, alleviating tenesmus symptoms, decreasing bellyache days and ameliorating abdominal distention. Any drug-related adverse reaction was not seen.
CONCLUSIONThe efficacy of CJT in treating DIBS is definite and without any toxic and adverse effects.
